Money Racket — Daily Brief, 2026-08-15
The catalysts that actually moved money this week — decoded. The headlines are free. The who-cashes-in is for subscribers.
1FDA Authorizes CLiK Extra for Screwworm Prevention in Livestock and Wildlife—Direct Beneficiary Unclear, Supplier Play Emerges
What happenedThe FDA issued an Emergency Use Authorization on August 7, 2026, for CLiK Extra (dicyclanil topical suspension) to prevent New World screwworm infestations in sheep, cattle, goats, swine, camelids, and certain wildlife species. The product is a wound spray applied directly to wounds to block screwworm infestation.
2FDA Approves Tudriqev for Refractory Melanoma—Oncology Combination Play with Nivolumab
What happenedThe FDA granted accelerated approval on August 6, 2026, to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral therapy, for advanced melanoma in combination with nivolumab (a PD-1 inhibitor) in patients who have progressed on prior PD-1 therapy. One in four patients responded, with median response duration of 14 months.
3Kimberly-Clark Secures $45M Tariff Refund—Partial Recovery on 2025 Tariff Exposure
What happenedKimberly-Clark (KMB) secured a $45 million tariff refund, representing roughly half of the tariffs it paid in 2025, according to Supply Chain Dive reporting on August 2026 tariff refund flows.
4Trump Executive Order on Childhood Vaccine Schedule—Potential Demand Shift Away from Combination Vaccines
What happenedPresident Trump signed an executive order in August 2026 calling for spacing out childhood vaccines and seeking to split combination vaccines (notably MMR) into separate shots, contrary to guidance from major medical organizations including the CDC and American Academy of Pediatrics.
This is one morning. Get it every morning.
The full brief lands in your inbox every market morning — Monday through Saturday at 7:45am ET, before the bell — with who cashes in on each catalyst and exactly what to watch. $40 a month. Never be last to the money again.
Get the brief — $40/mo